[Study on the efficacy and safety of sublingual immunotherapy with standardized @entity8786 drops for XXXX ].

@entity1 @entity8786 @entity7370 @entity2023
OBJECTIVE: To evaluate the efficacy and safety of the sublingual immunotherapy with @entity8786 drops on @entity1 with @entity2023 . METHOD: One hundred and twelve cases were collected from adult @entity1 with dust-mite @entity2023 of our hospital who could adhere to treatment and regular follow-up. These @entity1 were randomly allocated to receive either sublingual immunotherapy (SLIT group, n = 56) or medical treatment (Control group, n = 56). To evaluate the clinical efficacy by side effects which were registered, symptom and medication scores which were assessed and @entity7370 quality of life questionnaire (RQLQ) which was completed in the baseline and two years after treatment. RESULT: Dropouts after the 2 years' treatment were 5 of SLIT group and 4 of Control group respectively. SLIT group induced the significant reductions on both the symptom scores (7.81    3.14 to 3.89    2.01, P < 0.0 1) and the medication scores (2.86    0.75 to 0.44    0.06, P < 0.01). Meanwhile, Control group induced the reductions on both the symptom scores (8.01    3.32 to 5.20    2.43) and the medication scores (2.95    0.80 to 1.75    0.40). There were significant differences (P< 0. 01) in symptom and medication scores between the two groups after 2-year treatment. The @entity1 in SLIT group had fewer symptoms and lower intake of medication. There were statistically significant differences in RQLQ between SLIT group [19 (15,22)] and Control group [36 (26,47)] after two years treatment (Z = -5. 21, P < 0.01). SLIT group also had significant improvement in RQLQ (Z = -6.10, P < 0.01) between before and after the treatment. There were 4 @entity1 who showed adverse reactions in SLIT group (3 occurred in increment period, and 1 occurred in the maintenance period). The incidence of adverse reactions was 7.14%. No severe systemic side effects were registered. CONCLUSION: SLIT with standardized @entity8786 drops in China is safe and effective to @entity1 with @entity2023 .
